```html

Zollinger‑Ellison Ulcer Disease (Zollinger’s Ulcer)

Overview

Zollinger‑Ellison ulcer disease (ZES) is a rare disorder characterized by one or more gastrin‑producing tumors (gastrinomas) that arise primarily in the pancreas or duodenum. These tumors secrete excessive amounts of the hormone gastrin, which in turn stimulates the stomach lining to produce large volumes of gastric acid. The resulting hyperacidic environment leads to multiple, often refractory peptic ulcers, most commonly in the duodenum but also in the jejunum, stomach, and, occasionally, the esophagus.

Who it affects: ZES can occur at any age but most patients are diagnosed between 40 and 60 years old. Both sexes are affected equally, although a slight male predominance (≈55 %) has been reported in several series.

Prevalence: Gastrinomas are the second most common functional pancreatic neuroendocrine tumor (NET), accounting for ~20‑30 % of all pancreatic NETs. The overall incidence of ZES is estimated at 0.5–2 cases per million people per year, with roughly 10 % of cases associated with the hereditary Multiple Endocrine Neoplasia type 1 (MEN‑1) syndrome (≈1–2 % of all MEN‑1 patients develop gastrinomas). [Mayo Clinic, 2023; NIH, 2022]

Symptoms

Symptoms result mainly from acid‑related damage to the gastrointestinal (GI) tract and from mass effects of the tumor.

• Recurrent abdominal pain – usually epigastric, burning, or gnawing; may improve with antacids but often returns.
• Diarrhea – caused by acid inactivation of pancreatic enzymes and bile salts; can be watery, frequent, and may lead to dehydration.
• Steatorrhea (fatty stools) – malabsorption due to pancreatic enzyme inhibition.
• Heartburn / gastro‑esophageal reflux – excess acid refluxes into the esophagus.
• Nausea & vomiting – especially after meals.
• Weight loss – from malabsorption, chronic diarrhea, and reduced intake due to pain.
• Upper GI bleeding – melena (black, tarry stools) or hematemesis (vomiting blood) from ulcer erosion.
• Family history of MEN‑1 – consider if multiple endocrine tumors are present.

Because gastric acid output can be 10–100 times higher than normal, patients often have ulcers that are resistant to standard proton‑pump inhibitor (PPI) therapy and may develop new ulcers despite healing of older ones.

Causes and Risk Factors

Primary cause – Gastrinomas

Gastrinomas are neuroendocrine tumors that originate from enterochromaffin‑like cells. They are usually sporadic (≈90 %) but can be hereditary**.

• MEN‑1 syndrome – an autosomal‑dominant mutation in the MEN1 gene (menin) leads to tumors of the parathyroid, pituitary, and pancreas; ~20‑30 % of MEN‑1 patients develop gastrinomas.
• Familial gastrinoma syndrome – rare, inherited form without other MEN‑1 features.

Risk factors

• Age 40–60 years (peak incidence).
• Male sex (slight predominance).
• Family history of MEN‑1 or gastrinoma.
• Chronic atrophic gastritis or Helicobacter pylori infection (does NOT cause ZES but may coexist and worsen ulcer disease).

There are no known lifestyle risk factors (smoking, alcohol, NSAIDs) that directly cause gastrinomas, though they can exacerbate ulcer symptoms.

Diagnosis

Diagnosing ZES requires establishing two components: (1) markedly elevated fasting serum gastrin, and (2) evidence of gastric acid hypersecretion.

Laboratory tests

• Fasting serum gastrin level – values > 1000 pg/mL are highly suggestive; levels > 10× upper limit of normal with acidic gastric pH (<2) confirm the diagnosis. [Mayo Clinic, 2023]
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin (> 120 pg/mL increase) is characteristic for gastrinomas.
• Basic metabolic panel, CBC, and liver function tests – assess for complications (e.g., anemia, electrolyte loss).

Imaging studies

• Endoscopic ultrasound (EUS) – high sensitivity (≈70‑85 %) for detecting small pancreatic or duodenal gastrinomas.
• Multiphasic contrast‑enhanced CT or MRI – defines tumor size, location, and metastasis (especially to liver and lymph nodes).
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – gold standard for locating neuroendocrine tumors and assessing metastatic spread.

Endoscopic evaluation

Upper endoscopy (EGD) visualizes multiple ulcers, often > 3 cm apart, some beyond the duodenum (jejunum). Biopsies are taken to rule out H. pylori or malignancy.

Staging

Gastrinomas are staged using the TNM system for pancreatic NETs. Accurate staging guides therapy (surgical resection vs. medical management).

Treatment Options

Management combines control of acid hypersecretion, tumor-directed therapy, and surveillance.

Acid suppression – first line

• High‑dose proton‑pump inhibitors (PPIs) – omeprazole 60‑120 mg/day, esomeprazole 40‑80 mg/day, or equivalent. Doses are often 2–4× higher than for typical GERD and may need lifelong use. [Cleveland Clinic, 2022]
• PPIs are usually started before definitive tumor treatment to reduce ulcer complications.

Surgical options

• Curative resection – indicated for solitary, non‑metastatic gastrinomas. Enucleation or pancreaticoduodenectomy (Whipple) may be performed depending on size and location.
• Debulking surgery – for patients with limited metastatic disease; reduces tumor burden and gastrin output.
• In MEN‑1 patients, surgery is more controversial because of multifocal disease; individualized decision making is essential.

Medical therapies for unresectable or metastatic disease

• Somatostatin analogues (octreotide, lanreotide) – bind somatostatin receptors, suppress gastrin secretion, and may stabilize tumor growth. Doses: octreotide 30‑50 mg IM every 28 days.
• Targeted molecular therapy – everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are FDA‑approved for progressive pancreatic NETs; they can reduce tumor size and gastrin production.
• Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive tumors; improves progression‑free survival in metastatic gastrinomas.
• Cytotoxic chemotherapy (streptozocin‑based regimens) – reserved for high‑grade or rapidly progressive disease.

Supportive care

• Electrolyte replacement for chronic diarrhea (especially potassium and bicarbonate).
• Vitamin B12 supplementation if malabsorption is present.
• Regular monitoring of gastric pH or serum gastrin to titrate PPI dosing.

Living with Zollinger’s Ulcer Disease

Daily management tips

• Take PPIs exactly as prescribed – never skip doses; acid rebound can precipitate severe pain.
• Stay hydrated – aim for 2–3 L of fluid daily; oral rehydration solutions help replace lost electrolytes.
• Eat small, frequent meals – reduces gastric emptying stimulus and limits acid spikes.
• Limit foods that stimulate acid secretion: caffeine, carbonated drinks, very spicy or fatty meals.
• Monitor stool frequency and consistency – keep a log; inform your clinician of any sudden changes.
• Schedule regular follow‑up labs (gastrin, CBC, CMP) and imaging every 6–12 months per your oncologist’s recommendation.
• Consider joining a support group for NET patients; psychological health is an important component of chronic disease management.

Medication adherence

Set alarms or use a pill‑organizer. If you experience side effects such as headache or mild GI upset from PPIs, discuss dose adjustments rather than discontinuing.

Travel and work

Carry a written medication list, a spare supply of PPIs, and an emergency contact card. For jobs that involve heavy lifting or shift work, discuss timing of medication to maintain consistent acid control.

Prevention

Because gastrinomas are largely sporadic or genetically driven, primary prevention is limited. However, the following measures can reduce secondary complications:

• Screen individuals with a known MEN‑1 mutation with annual fasting gastrin and imaging starting at age 10‑15 (per NIH guidelines).
• Eradicate Helicobacter pylori infection if present – it can aggravate ulcer disease.
• Avoid chronic NSAID or aspirin use unless medically indicated; use gastro‑protective agents if unavoidable.
• Maintain a healthy weight and balanced diet to lessen the burden of reflux and diarrhea.

Complications

If untreated or inadequately managed, ZES can lead to serious health problems:

• Perforated peptic ulcer – emergency surgery required; risk increases with ulcer size and location.
• Severe GI bleeding – may necessitate endoscopic hemostasis, angiographic embolization, or surgery.
• Gastric outlet obstruction – from scarring or tumor mass effect.
• Malnutrition and weight loss – due to chronic diarrhea, steatorrhea, and reduced intake.
• Liver metastases – occur in ~30‑50 % of gastrinomas at diagnosis; affect prognosis.
• Bone demineralization – chronic metabolic acidosis can lead to secondary hyperparathyroidism.
• Reduced quality of life – frequent pain, hospital visits, and medication side effects.

Overall 5‑year survival for localized gastrinoma exceeds 90 % with curative surgery, but drops to 50‑60 % when liver metastases are present. [WHO Neuroendocrine Tumor Guidelines, 2021]

When to Seek Emergency Care

```